South Carolina is currently home to 1220 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-006 - Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
NCT05697198
Recruiting
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic mali... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Clinical Site, Rock Hill, South Carolina
Conditions: Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Register for Updates
Effect of Mobilization With Movement on Weight Bearing Ankle Dorsiflexion Range of Motion
NCT05844072
Recruiting
Limited ankle range of motion is associated with increased risk for ankle sprains, knee joint dysfunction and injury to the ACL. Therefore, it is important that researchers and clinicians understand the best treatment options to increase ankle range of motion for injury prevention. We are recruiting adults with limited ankle range of motion who are lacking current ankle injuries for a treatment investigation. All study procedures will occur on the campus of the University of South Carolina by a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2023
Locations: Blatt Physical education Building, Columbia, South Carolina
Conditions: Ankle Joint Contracture
Register for Updates
Immediate and 24-hour Effects of HyperVolt, Body Tempering, and Cupping Compared to Stretching on Hamstring Flexibility
NCT05793242
Recruiting
The purpose of this study is to compare the effects of the HyperVolt percussive massage device, body tempering, and dry cupping to static stretching of the hamstrings of healthy adults aged 18-39 years on the active knee extension and back saver sit-and-reach test.While these modalities are frequently used in healthcare settings there is a paucity of research regarding effectiveness. If the effects on flexibility are comparable, patients could save time and money by performing static stretching.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
04/24/2023
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Hamstring Contractures, Muscle Tightness
Register for Updates
Optetrak Knee System Post Market Clinical Follow-Up
NCT05788757
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Optetrak Knee System
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Medical University South Carolina, Charleston, South Carolina
Conditions: Knee Arthroplasty, Total
Register for Updates
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System
NCT05653102
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant® Knee System
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Medical University South Carolina, Charleston, South Carolina
Conditions: Knee Arthroplasty, Total
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. Howe... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2023
Locations: Prisma Health, Greenville, South Carolina
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
NCT05023655
Recruiting
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A mutated malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/14/2023
Locations: Prisma Health Cancer Institute, Greenville, South Carolina
Conditions: Solid Tumor, ARID1A Gene Mutation
Register for Updates
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
All
Ages:
Between 1 day and 30 days
Trial Updated:
04/12/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Congenital Heart Disease in Children
Register for Updates
FLEX FIRST Registry Research Protocol
NCT05616104
Recruiting
Prospective, observational study evaluating the clinical use and outcomes of the FLEX Vessel Prep (VP) system in arteriovenous fistulae or grafts presenting with clinical or hemodynamic abnormalities following 12 months post treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2023
Locations: Dialysis Access Institute, Orangeburg, South Carolina
Conditions: Arteriovenous Fistula, Arteriovenous Graft, Fistula, Arterial Occlusive Diseases
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Vista Clinical Research, Columbia, South Carolina
Conditions: Lung Cancer
Register for Updates
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590
Recruiting
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with stand... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Prisma Health, Institute for Translational Oncology Research, Greenville, South Carolina
Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Register for Updates